Ardelyx prices upsized IPO at $14 midpoint

Comment

Shutterstock photo

Ardelyx, which is developing therapies to control the progression of late-stage kidney disease, raised $60 million by offering 4.3 million shares (vs. 3.6 million originally planned) at $14, the midpoint of its $13 to $15 range. Ardelyx will list on the NASDAQ under the symbol ARDX. Citi and Leerink Partners acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com